Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150213 · ClinicalTrials.gov registry record · Phase 2
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT02150213: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT02150213 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02150213, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).
Primary Outcome
Incidence of adrenal cortical adenomas as assessed by non-contrast MRI of the abdomen (CT or ultrasound of the abdomen was permitted if MRI was contraindication)
Interventions
- PROCEDURE Biopsy
- DRUG BGG492
- PROCEDURE MRI, CT or ultrasound was permitted if MRI was contraindicated
- PROCEDURE Dexamethasone Supression Test
- PROCEDURE Sonogram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
What the finished NCT02150213 record still lists
NCT02150213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 5 interventions - of which Biopsy is the first listed.
NCT02150213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02150213 about?
NCT02150213 is a clinical study titled "Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492". To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).
What is the current status of trial NCT02150213?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2014-08. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02150213?
The interventions under investigation include: Biopsy (PROCEDURE), BGG492 (DRUG), MRI, CT or ultrasound was permitted if MRI was contraindicated (PROCEDURE), Dexamethasone Supression Test (PROCEDURE), Sonogram (PROCEDURE).
Who is sponsoring clinical trial NCT02150213?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02150213's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia